RJA
EXAS

Raymond James & Associates’s Exact Sciences EXAS Stock Holding History

Raymond James & Associates’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$3.86M Sell
56,607
-3,518
-6% -$199K ﹤0.01% 1833
2024
Q2 		$2.54M Sell
60,125
-4,839
-7% -$266K ﹤0.01% 2014
2024
Q1 		$4.49M Buy
64,964
+2,039
+3% +$129K ﹤0.01% 1667
2023
Q4 		$4.66M Buy
62,925
+3,430
+6% +$225K ﹤0.01% 1587
2023
Q3 		$4.06M Buy
59,495
+2,435
+4% +$207K ﹤0.01% 1600
2023
Q2 		$5.36M Sell
57,060
-1,690
-3% -$132K ﹤0.01% 1432
2023
Q1 		$3.98M Sell
58,750
-14,704
-20% -$945K ﹤0.01% 1625
2022
Q4 		$3.64M Buy
73,454
+56
+0.1% +$2.29K ﹤0.01% 1635
2022
Q3 		$2.38M Sell
73,398
-11,353
-13% -$468K ﹤0.01% 1867
2022
Q2 		$3.34M Sell
84,751
-1,152
-1% -$61.6K ﹤0.01% 1679
2022
Q1 		$6.01M Buy
85,903
+6,102
+8% +$446K 0.01% 1380
2021
Q4 		$6.21M Buy
79,801
+680
+0.9% +$60K 0.01% 1408
2021
Q3 		$7.55M Buy
79,121
+14,033
+22% +$1.48M 0.01% 1229
2021
Q2 		$8.09M Buy
65,088
+6,787
+12% +$810K 0.01% 1191
2021
Q1 		$7.68M Sell
58,301
-12,392
-18% -$1.7M 0.01% 1180
2020
Q4 		$9.37M Buy
70,693
+15,204
+27% +$1.84M 0.01% 994
2020
Q3 		$5.66M Buy
55,489
+347
+0.6% +$30K 0.01% 1158
2020
Q2 		$4.79M Sell
55,142
-16,392
-23% -$1.31M 0.01% 1208
2020
Q1 		$4.15M Sell
71,534
-24,828
-26% -$2.02M 0.01% 1151
2019
Q4 		$8.91M Buy
96,362
+3,394
+4% +$298K 0.01% 956
2019
Q3 		$8.4M Buy
92,968
+26,423
+40% +$3.01M 0.01% 943
2019
Q2 		$7.86M Buy
66,545
+1,919
+3% +$193K 0.01% 978
2019
Q1 		$5.6M Buy
64,626
+4,284
+7% +$365K 0.01% 1131
2018
Q4 		$3.81M Sell
60,342
-3,132
-5% -$215K 0.01% 1235
2018
Q3 		$5.01M Sell
63,474
-15,471
-20% -$1.01M 0.01% 1217
2018
Q2 		$4.72M Sell
78,945
-11,418
-13% -$614K 0.01% 1221
2018
Q1 		$3.64M Sell
90,363
-8,414
-9% -$410K 0.01% 1327
2017
Q4 		$5.19M Buy
98,777
+1,168
+1% +$62.4K 0.01% 1105
2017
Q3 		$4.6M Buy
97,609
+5,537
+6% +$223K 0.01% 1129
2017
Q2 		$3.26M Sell
92,072
-9,725
-10% -$300K 0.01% 1264
2017
Q1 		$2.4M Sell
101,797
-10,012
-9% -$198K 0.01% 1421
2016
Q4 		$1.49M Sell
111,809
-6,875
-6% -$111K ﹤0.01% 1683
2016
Q3 		$2.2M Sell
118,684
-66,892
-36% -$1.18M 0.01% 1386
2016
Q2 		$2.27M Buy
185,576
+140,155
+309% +$1.06M 0.01% 1258
2016
Q1 		$306K Buy
45,421
+9,800
+28% +$62.7K ﹤0.01% 2314
2015
Q4 		$329K Sell
35,621
-38,779
-52% -$361K ﹤0.01% 2158
2015
Q3 		$1.34M Buy
74,400
+27,650
+59% +$635K 0.01% 1441
2015
Q2 		$1.39M Buy
46,750
+30,645
+190% +$770K 0.01% 1547
2015
Q1 		$355K Buy
16,105
+1,964
+14% +$49.8K ﹤0.01% 2162
2014
Q4 		$388K Sell
14,141
-3,899
-22% -$94.9K ﹤0.01% 2047
2014
Q3 		$350K Sell
18,040
-10
-0.1% -$183 ﹤0.01% 1984
2014
Q2 		$307K Buy
18,050
+1,300
+8% +$17.9K ﹤0.01% 2035
2014
Q1 		$237K Sell
16,750
-800
-5% -$10.8K ﹤0.01% 2039
2013
Q4 		$206K Sell
17,550
-65,603
-79% -$753K ﹤0.01% 1949
2013
Q3 		$981K Buy
83,153
+67,403
+428% +$865K 0.01% 1274
2013
Q2 		$219K Buy
+15,750
New +$171K ﹤0.01% 1818

Other funds holding EXAS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Raymond James & Associates's EXAS Position: Q3 2024 in Review

Raymond James & Associates reduced its Exact Sciences (EXAS) stake by 5.9% in Q3 2024, selling an estimated $199K and leaving 56,607 shares worth $3.86M. The position accounts for ﹤0.01% of the portfolio, ranked #1833.

Raymond James & Associates first reported a position in EXAS in Q2 2013 and has held it in 46 quarters since. The position peaked at $9.37M in Q4 2020. 599 funds tracked by Wall St. Rank hold EXAS as of Q3 2024.

  • Raymond James & Associates held 56,607 shares of Exact Sciences worth $3.86M as of Q3 2024.
  • Raymond James & Associates sold 3,518 Exact Sciences shares in Q3 2024, an estimated $199K.
  • Exact Sciences made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1833 holding.
  • Raymond James & Associates first reported a position in Exact Sciences in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's Exact Sciences position peaked at $9.37M in Q4 2020.
  • 599 funds tracked by Wall St. Rank held Exact Sciences as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.